Werewolf Therapeutics(HOWL) - 2024 Q1 - Quarterly Results

Exhibit 99.1 Werewolf Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update – Company announces cash runway extension through at least the first quarter of 2026 — Watertown, Mass., May 3, 2024 – Werewolf Therapeutics, Inc. (the "Company" or "Werewolf") (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated ...